Compare Divis Laboratories with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs CADILA HEALTHCARE - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES CADILA HEALTHCARE DIVIS LABORATORIES/
CADILA HEALTHCARE
 
P/E (TTM) x 32.3 14.4 224.1% View Chart
P/BV x 7.3 2.8 258.9% View Chart
Dividend Yield % 0.6 1.5 42.3%  

Financials

 DIVIS LABORATORIES   CADILA HEALTHCARE
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
CADILA HEALTHCARE
Mar-18
DIVIS LABORATORIES/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,142558 204.6%   
Low Rs533362 147.5%   
Sales per share (Unadj.) Rs146.6116.3 126.1%  
Earnings per share (Unadj.) Rs33.017.9 184.9%  
Cash flow per share (Unadj.) Rs38.423.1 166.0%  
Dividends per share (Unadj.) Rs10.003.50 285.7%  
Dividend yield (eoy) %1.20.8 156.9%  
Book value per share (Unadj.) Rs222.885.4 260.9%  
Shares outstanding (eoy) m265.471,023.74 25.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.74.0 144.5%   
Avg P/E ratio x25.325.7 98.5%  
P/CF ratio (eoy) x21.819.9 109.7%  
Price / Book Value ratio x3.85.4 69.8%  
Dividend payout %30.319.6 154.5%   
Avg Mkt Cap Rs m222,318470,664 47.2%   
No. of employees `00010.811.8 91.1%   
Total wages/salary Rs m4,56118,545 24.6%   
Avg. sales/employee Rs Th3,616.010,072.7 35.9%   
Avg. wages/employee Rs Th423.81,569.1 27.0%   
Avg. net profit/employee Rs Th814.91,547.7 52.7%   
INCOME DATA
Net Sales Rs m38,915119,049 32.7%  
Other income Rs m1,1341,132 100.2%   
Total revenues Rs m40,049120,181 33.3%   
Gross profit Rs m12,61728,475 44.3%  
Depreciation Rs m1,4255,388 26.4%   
Interest Rs m13911 1.5%   
Profit before tax Rs m12,31323,308 52.8%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,5435,644 62.8%   
Profit after tax Rs m8,77018,292 47.9%  
Gross profit margin %32.423.9 135.6%  
Effective tax rate %28.824.2 118.8%   
Net profit margin %22.515.4 146.7%  
BALANCE SHEET DATA
Current assets Rs m45,35182,005 55.3%   
Current liabilities Rs m6,50760,720 10.7%   
Net working cap to sales %99.817.9 558.3%  
Current ratio x7.01.4 516.0%  
Inventory Days Days12773 173.2%  
Debtors Days Days9598 96.8%  
Net fixed assets Rs m21,16083,703 25.3%   
Share capital Rs m5311,024 51.8%   
"Free" reserves Rs m58,62586,421 67.8%   
Net worth Rs m59,15687,445 67.6%   
Long term debt Rs m025,551 0.0%   
Total assets Rs m67,832180,653 37.5%  
Interest coverage x926.826.6 3,486.2%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.7 87.1%   
Return on assets %12.910.6 121.8%  
Return on equity %14.820.9 70.9%  
Return on capital %20.822.0 94.8%  
Exports to sales %00-   
Imports to sales %21.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35942,683 75.8%   
Fx outflow Rs m9,04211,242 80.4%   
Net fx Rs m23,31731,441 74.2%   
CASH FLOW
From Operations Rs m7,7599,193 84.4%  
From Investments Rs m-4,783-9,737 49.1%  
From Financial Activity Rs m-3,142515 -610.0%  
Net Cashflow Rs m-166-29 572.4%  

Share Holding

Indian Promoters % 52.0 74.8 69.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 8.3 142.2%  
FIIs % 19.0 5.9 322.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 11.0 156.4%  
Shareholders   31,796 44,069 72.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   GLENMARK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  BIOCON   UNICHEM LAB  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Over 100 Points Down; Banking and IT Stocks Under Pressure(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.9% while the Hang Seng is also down 0.9%.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 17, 2019 09:57 AM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - ORCHID PHARMA LTD COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS